Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
CSE:ZEAL
Price:
600 DKK
-2.99%
Updated:
May 20, 2024
Zealand Pharma A/S
Cash from Operating Activities
|
Zealand Pharma A/S
Cash from Operating Activities Peer Comparison
Comparables:
GMAB
ASND
B
BAVA
BIOPOR
SANION
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash from Operating Activities
-kr425.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-10%
|
|
|
Genmab A/S
CSE:GMAB
|
Cash from Operating Activities
kr5.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash from Operating Activities
-€320.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash from Operating Activities
kr1.8B
|
CAGR 3-Years
343%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash from Operating Activities
-kr49.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-11%
|
|
|
Saniona AB
STO:SANION
|
Cash from Operating Activities
-kr85.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
See Also
What is Zealand Pharma A/S's Cash from Operating Activities?
Cash from Operating Activities
-425.7m
DKK
-425.7m
DKK
Based on the financial report for Dec 31, 2023, Zealand Pharma A/S's Cash from Operating Activities amounts to -425.7m DKK.
What is Zealand Pharma A/S's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-10%
-10%
Over the last year, the Cash from Operating Activities growth was 55%. The average annual Cash from Operating Activities growth rates for Zealand Pharma A/S have been 15% over the past three years , 2% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
